Politics and Government
Source : (remove) : STAT
RSS • JSON • XML • CSV
Politics and Government
Source : (remove) : STAT
RSS • JSON • XML • CSV

Metsera's drug shows potential in early clinical trial


  Copy link into your clipboard //politics-government.news-articles.net/content/ .. rug-shows-potential-in-early-clinical-trial.html
  Print publication without navigation Published in Politics and Government on by STAT
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source


  And other biotech news stories brought to you by The Readout.

The article from STAT News dated June 9, 2025, discusses several key developments in the biotech industry. Merck has acquired Eyebiotech for $3 billion to bolster its ophthalmology offerings, while Keros Therapeutics reported positive results from a Phase 2 trial of KER-050 for treating anemia in patients with myelodysplastic syndromes. Metsera, a new company focused on metabolic diseases, launched with $290 million in funding. Axsome Therapeutics received FDA approval for its migraine treatment, AXS-07. The European Medicines Agency (EMA) is set to review the safety of GLP-1 receptor agonists due to concerns over potential side effects. Additionally, the National Institutes of Health (NIH) is facing budget cuts that could impact research funding. Lastly, Amylin Pharmaceuticals is exploring a potential acquisition to expand its portfolio in diabetes and obesity treatments.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/09/biotech-news-merck-keros-metsera-axsome-ema-nih-cuts-amylin-the-readout/ ]

Publication Contributing Sources